Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $29.48 and traded as high as $29.91. Assembly Biosciences shares last traded at $29.60, with a volume of 81,200 shares traded.

Wall Street Analyst Weigh In

ASMB has been the topic of a number of research reports. Mizuho set a $40.00 price objective on shares of Assembly Biosciences and gave the stock an “outperform” rating in a research note on Thursday, November 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a report on Monday, December 22nd. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $41.75.

Assembly Biosciences Stock Performance

The company has a 50 day moving average of $28.82 and a two-hundred day moving average of $29.48. The stock has a market cap of $468.27 million, a PE ratio of -6.18 and a beta of 1.11.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Bank of America Corp DE grew its stake in Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 3,319 shares during the period. Seven Fleet Capital Management LP purchased a new stake in Assembly Biosciences in the 4th quarter worth $147,000. Charles Schwab Investment Management Inc. acquired a new position in Assembly Biosciences during the fourth quarter worth $228,000. Virtus Investment Advisers LLC acquired a new position in Assembly Biosciences during the fourth quarter worth $251,000. Finally, Engineers Gate Manager LP purchased a new position in Assembly Biosciences during the fourth quarter valued at $353,000. 19.92% of the stock is owned by institutional investors and hedge funds.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.